about
Cancer-associated thrombotic microangiopathySystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesAntineoplastic agents and thrombotic microangiopathy.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.Coagulation and cancer: biological and clinical aspects.Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report.Multiple recurrent ischaemic strokes in a patient with cancer: is there a role for the initiation of anticoagulation therapy for secondary stroke prevention?Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.Complications neurologiques des traitements anticancéreux
P2860
Q26738984-B437D8D5-AA2C-4615-B8AA-9B12494E3BD6Q28080469-B5A12386-8BD1-4699-BAD6-B154A9286022Q30251919-F56E8AC6-4BD8-4805-8293-7FD695B24BD2Q33398485-5EC7BB8B-BB9B-45F4-86DF-567D42C15190Q33419794-BBA275EA-0B75-4D77-888B-3E74E15939D7Q33421178-96724109-47B1-4F7E-BA9B-56F93741E854Q33423350-EC56A224-C88C-4489-8A5F-C4E8999D90DEQ33705135-F28E022E-A716-4BBA-A537-77ECE9D45619Q35025682-E5C10CF7-34B4-4C3C-842B-D114965DBE61Q36058502-B8DF6B11-5126-4C10-8917-553FE6A6EE84Q36977417-1811942A-A8AD-445E-979B-73A5B55B8D3EQ38070918-FDDDCDD4-C338-4D45-BBF1-1C195F62902AQ38087506-06FCDEFE-42EC-47F6-89C8-133D78AD101BQ38445683-6F140A03-A564-4F97-B6B5-2449EAE9E1B2Q38827793-BCA70760-E77D-48DA-ACAB-36EAE3841672Q41146886-A5D2679C-0C3B-408D-84D7-400C87DF5FD5Q41172212-991E38D6-809F-4AF6-A87E-CA4394C34680Q47120870-034FFCB7-6EDF-45E9-9BB8-EC1F40FA9D32Q48244563-259D40F0-AB18-4B35-99C1-92296E321693Q58929158-C7551D43-F1C0-4CA1-AFE5-53009FE276FB
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Thrombotic microangiopathy with targeted cancer agents
@ast
Thrombotic microangiopathy with targeted cancer agents
@en
Thrombotic microangiopathy with targeted cancer agents
@nl
type
label
Thrombotic microangiopathy with targeted cancer agents
@ast
Thrombotic microangiopathy with targeted cancer agents
@en
Thrombotic microangiopathy with targeted cancer agents
@nl
prefLabel
Thrombotic microangiopathy with targeted cancer agents
@ast
Thrombotic microangiopathy with targeted cancer agents
@en
Thrombotic microangiopathy with targeted cancer agents
@nl
P2093
P2860
P3181
P1476
Thrombotic microangiopathy with targeted cancer agents
@en
P2093
John A Blake-Haskins
Robert J Kreitman
Robert J Lechleider
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-11-0804
P407
P577
2011-09-15T00:00:00Z